NASDAQ · KROS
Keros Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for KROS: Nov 4, 2026
Keros Therapeutics, Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.96. The reported EPS for the same quarter last year was $-0.18.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.96 | $-0.65 | $-1.53 | 3 |
| Dec 2026 | $-1.72 | $-1.49 | $-1.97 | 3 |
| Mar 2027 | $-2.10 | $-2.10 | $-2.10 | 1 |
| Jun 2027 | $-2.21 | $-2.21 | $-2.21 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · Zacks · RTTNews · BNK Invest- MarketBeat · Oct 22, 7:04 PM EDTKeros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center StageKeros Therapeutics (NASDAQ:KROS) is repositioning its pipeline around rinvatercept, a skeletal-muscle regeneration candidate being developed for neuromuscular diseases, while its partnered program eleriscept advances through late-stage development under Takeda, Chief Executive Of
- Zacks · Oct 7, 1:30 PM EDTCan Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?Reblozyl's strong growth is helping Bristol Myers offset declining legacy drug sales, with new indications offering further upside.
- Zacks · Sep 29, 9:17 AM EDTKROS Begins Dosing in Phase II Study With Rinvatercept in DMDKeros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.
- RTTNews · Sep 9, 1:11 AM EDTKeros Therapeutics Authorises $ 5 Mln Share Buyback Following Elritercept Milestone; Stock Up(RTTNews) – Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company announced that its board approved a $5 million share repurchase program after receiving a $20 million elritercept milestone payment from its partner Takeda Pharmaceuticals, following the dosin
- Zacks · Sep 2, 11:30 AM EDTWhy Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks · Aug 24, 12:53 PM EDTKROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays WeakKeros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.
- Zacks · Aug 24, 12:51 PM EDTShould You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.
- Zacks · Aug 4, 10:43 AM EDTKROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in FocusKeros posts a wider Q2 loss as revenues fall to zero, while cash runway into H1 2028 and rinvatercept pipeline milestones keep attention on future growth.
- Zacks · Jul 30, 5:05 AM EDTNew Strong Sell Stocks for July 30thITRG, BEEM and KROS have been added to the Zacks Rank #5 (Strong Sell) List on July 30, 2026.
- Zacks · Jul 28, 8:15 AM EDTIncyte (INCY) Q2 Earnings and Revenues Top EstimatesIncyte (INCY) delivered earnings and revenue surprises of +54.50% and +14.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- BNK Invest · Jul 20, 3:38 PM EDTMonday 7/20 Insider Buying Report: NVA, KROSBargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we
- Zacks · Jun 26, 10:41 AM EDTNurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Keros Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.